Federal Register Notice: FDA is making available a draft guidance, Classifying Significant Postmarket Drug Safety Issues. It describes the agency’s current approach to classifying a significant postmarket drug safety issue as a “priority'' tracked safety issue (TSI) or a “standard” TSI, with the capability of elevating some priority TSIs to an “emergency” status. To download this guidance, click here. To view this notice, click here.
